
Kousuke Watanabe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9417158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. Scientific Reports, 2021, 11, 11617.	3.3	9
2	Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.3	2
3	Integrin α11 in non–small cell lung cancer is associated with tumor progression and postoperative recurrence. Cancer Science, 2020, 111, 200-208.	3.9	24
4	NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. Oncotarget, 2020, 11, 3590-3600.	1.8	8
5	Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab. Drug Discoveries and Therapeutics, 2019, 13, 164-167.	1.5	14
6	Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, e31-e34.	1.1	3
7	Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. European Journal of Cancer, 2019, 107, 93-96.	2.8	17
8	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review. BMC Cancer, 2019, 19, 52.	2.6	5
9	Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 303-307.	1.3	21
10	Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. Cancer Science, 2018, 109, 3326-3335.	3.9	32
11	Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0203625.	2.5	30
12	High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence. Japanese Journal of Clinical Oncology, 2017, 47, 543-550.	1.3	7
13	Histone methylationâ€mediated silencing of miRâ€139 enhances invasion of nonâ€smallâ€cell lung cancer. Cancer Medicine, 2015, 4, 1573-1582.	2.8	41
14	The chimeric transcript RUNX1–GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer. Japanese Journal of Clinical Oncology, 2015, 46, hyv187.	1.3	1
15	Oncogenic TPM3-ALK activation requires dimerization through theÂcoiled-coil structure of TPM3. Biochemical and Biophysical Research Communications, 2015, 457, 457-460.	2.1	20
16	Alternative polyadenylation is associated with lower expression of <scp>PABPN</scp> 1 and poor prognosis in nonâ€small cell lung cancer. Cancer Science, 2014, 105, 1135-1141.	3.9	36
17	Detection of novel paraja ring finger 2â€fer tyrosine kinase <scp>mRNA</scp> chimeras is associated with poor postoperative prognosis in nonâ€small cell lung cancer. Cancer Science, 2013, 104, 1447-1454.	3.9	12
18	Disruption of the expression and function of microRNAs in lung cancer as a result of epigenetic changes. Frontiers in Genetics, 2013, 4, 275.	2.3	17

#	Article	IF	CITATIONS
19	FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2013, 6, 598-612.	0.5	16
20	Pulmonary Venous Invasion, Determined by Chest Computed Tomographic Scan, as a Potential Early Indicator of Zygomycosis Infection. Journal of Thoracic Imaging, 2012, 27, W97-W99.	1.5	0
21	Genome structureâ€based screening identified epigenetically silenced microRNA associated with invasiveness in nonâ€smallâ€cell lung cancer. International Journal of Cancer, 2012, 130, 2580-2590.	5.1	83
22	CpG island methylation of microRNAs is associated with tumor size and recurrence of nonâ€smallâ€cell lung cancer. Cancer Science, 2011, 102, 2126-2131.	3.9	33
23	Polymerase reaction without primers throughout for the reconstruction of full-length cDNA from products of rapid amplification of cDNA ends (RACE). Biotechnology Letters, 2011, 33, 1301-1307.	2.2	4
24	Identification of <i>GOS2</i> as a gene frequently methylated in squamous lung cancer by combination of <i>in silico</i> and experimental approaches. International Journal of Cancer, 2010, 126, 1895-1902.	5.1	48
25	Treatment of PCR products with exonuclease I and heat-labile alkaline phosphatase improves the visibility of combined bisulfite restriction analysis. Biochemical and Biophysical Research Communications, 2010, 399, 422-424.	2.1	9
26	Impact of DNA demethylation of the GOS2 gene on the transcription of GOS2 in squamous lung cancer cell lines with or without nuclear receptor agonists. Biochemical and Biophysical Research Communications, 2009, 390, 1283-1287.	2.1	31